Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece
Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.151
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2017
Authors
Publisher
Elsevier BV